Albany Molecular Research Inc. (AMRI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.91+0.14 (+0.95%)
As of 12:09 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close14.77
Bid14.85 x 200
Ask14.88 x 200
Day's Range14.74 - 15.15
52wk Range12.45 - 21.69
1y Target EstN/A
Market Cap620.48M
P/E Ratio (ttm)-15.28
Avg Vol (3m)256,553
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire4 hours ago

    AMRI CEO to Present at Baird 2016 Global Healthcare Conference

    ALBANY, N.Y., Aug. 24, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Baird ...

  • PR Newswire20 hours ago

    AMRI Licenses CRISPR-Cas9 Gene Editing Technology

    ALBANY, N.Y., Aug. 23, 2016 /PRNewswire/ -- AMRI (AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. "While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has significant utility that are critical to our customers' R&D projects, notably drug target assessment and in vitro model development for lead discovery and optimization," said Christopher Conway, Senior Vice President, Discovery and Development Services at AMRI.

  • GlobeNewswireyesterday

    Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares announced by Shareholders Foundation

    SAN DIEGO, Aug. 23, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit is pending in New York on behalf of certain purchasers of shares of Albany Molecular Research, Inc. over alleged Securities ...